Literature DB >> 15899772

Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry.

James Huang1, Guang Fan, Yanping Zhong, Ken Gatter, Rita Braziel, Gary Gross, Antony Bakke.   

Abstract

The diagnosis of B-cell chronic lymphoproliferative disorders is a great challenge when made in a background of polyclonal B cells. We studied the diagnostic usefulness of aberrant CD22 expression for differentiating neoplastic from benign B cells by 4-color flow cytometry. Of 56 cases of B-cell chronic lymphoproliferative disorders, we found that neoplastic cells showed aberrant CD22 expression in 39 (70%) of 56 cases, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, hairy cell leukemia, and follicular lymphoma. In 4 cases, monoclonality was detected definitively only by evaluating the immunoglobulin light chain restriction in B cells with aberrant CD22 expression because numerous polyclonal B cells were present. Aberrant CD22 expression is a useful marker for detection of monoclonal B cells admixed with numerous benign polyclonal B cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899772     DOI: 10.1309/KPXN-VR7X-4AME-NBBE

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Variables affecting the quantitation of CD22 in neoplastic B cells.

Authors:  Gregory A Jasper; Indu Arun; David Venzon; Robert J Kreitman; Alan S Wayne; Constance M Yuan; Gerald E Marti; Maryalice Stetler-Stevenson
Journal:  Cytometry B Clin Cytom       Date:  2010-09-24       Impact factor: 3.058

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

Authors:  Weihsu C Chen; Gladys C Completo; Darren S Sigal; Paul R Crocker; Alan Saven; James C Paulson
Journal:  Blood       Date:  2010-02-24       Impact factor: 22.113

4.  Molecular dynamics simulations, docking and MMGBSA studies of newly designed peptide-conjugated glucosyloxy stilbene derivatives with tumor cell receptors.

Authors:  Mia I Rico; Charlotta G Lebedenko; Saige M Mitchell; Ipsita A Banerjee
Journal:  Mol Divers       Date:  2022-01-17       Impact factor: 3.364

5.  A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.

Authors:  Barbara W Grant; Sin-Ho Jung; Jeffrey L Johnson; Lale Kostakoglu; Eric Hsi; John C Byrd; Jeffrey Jones; John P Leonard; S Eric Martin; Bruce D Cheson
Journal:  Cancer       Date:  2013-08-06       Impact factor: 6.860

6.  Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.

Authors:  Danijela Jovanovic; Predrag Djurdjevic; Nebojsa Andjelkovic; Ljubica Zivic
Journal:  Contemp Oncol (Pozn)       Date:  2014-01-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.